172 related articles for article (PubMed ID: 16413384)
1. The new face of bispecific antibodies: targeting cancer and much more.
Lum LG; Davol PA; Lee RJ
Exp Hematol; 2006 Jan; 34(1):1-6. PubMed ID: 16413384
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
[TBL] [Abstract][Full Text] [Related]
3. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
4. Antibody targeting of stem cells to infarcted myocardium.
Lee RJ; Fang Q; Davol PA; Gu Y; Sievers RE; Grabert RC; Gall JM; Tsang E; Yee MS; Fok H; Huang NF; Padbury JF; Larrick JW; Lum LG
Stem Cells; 2007 Mar; 25(3):712-7. PubMed ID: 17138964
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
Kipriyanov SM; Le Gall F
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
[TBL] [Abstract][Full Text] [Related]
6. Targeting T cells with bispecific antibodies for cancer therapy.
Lum LG; Thakur A
BioDrugs; 2011 Dec; 25(6):365-79. PubMed ID: 22050339
[TBL] [Abstract][Full Text] [Related]
7. Bispecific T-cell engaging antibodies for cancer therapy.
Baeuerle PA; Reinhardt C
Cancer Res; 2009 Jun; 69(12):4941-4. PubMed ID: 19509221
[TBL] [Abstract][Full Text] [Related]
8. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibodies for cancer therapy.
Chames P; Baty D
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873
[TBL] [Abstract][Full Text] [Related]
10. Diabodies: molecular engineering and therapeutic applications.
Wu C
Drug News Perspect; 2009 Oct; 22(8):453-8. PubMed ID: 20016854
[TBL] [Abstract][Full Text] [Related]
11. BiTE: Teaching antibodies to engage T-cells for cancer therapy.
Baeuerle PA; Kufer P; Bargou R
Curr Opin Mol Ther; 2009 Feb; 11(1):22-30. PubMed ID: 19169956
[TBL] [Abstract][Full Text] [Related]
12. Recombinant bispecific antibodies for cellular cancer immunotherapy.
Müller D; Kontermann RE
Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
[TBL] [Abstract][Full Text] [Related]
13. Activated T cells armed with bispecific antibodies kill tumor targets.
Bhutani D; Lum LG
Curr Opin Hematol; 2015 Nov; 22(6):476-83. PubMed ID: 26457960
[TBL] [Abstract][Full Text] [Related]
14. BiTEs: bispecific antibody constructs with unique anti-tumor activity.
Wolf E; Hofmeister R; Kufer P; Schlereth B; Baeuerle PA
Drug Discov Today; 2005 Sep; 10(18):1237-44. PubMed ID: 16213416
[TBL] [Abstract][Full Text] [Related]
15. Targeting of Lin-Sca+ hematopoietic stem cells with bispecific antibodies to injured myocardium.
Lum LG; Fok H; Sievers R; Abedi M; Quesenberry PJ; Lee RJ
Blood Cells Mol Dis; 2004; 32(1):82-7. PubMed ID: 14757418
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibodies, nanoparticles and cells: bringing the right cells to get the job done.
Tang J; Shen D; Zhang J; Ligler FS; Cheng K
Expert Opin Biol Ther; 2015; 15(9):1251-5. PubMed ID: 26004388
[TBL] [Abstract][Full Text] [Related]
17. Bi-specific antibody therapy for the treatment of cancer.
Withoff S; Helfrich W; de Leij LF; Molema G
Curr Opin Mol Ther; 2001 Feb; 3(1):53-62. PubMed ID: 11249732
[TBL] [Abstract][Full Text] [Related]
18. Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer. Bench to bedside.
Lum LG; Sen M
Acta Haematol; 2001; 105(3):130-6. PubMed ID: 11463985
[TBL] [Abstract][Full Text] [Related]
19. Current perspectives of bispecific antibody-based immunotherapy.
Talac R; Nelson H
J Biol Regul Homeost Agents; 2000; 14(3):175-81. PubMed ID: 11037049
[TBL] [Abstract][Full Text] [Related]
20. Selection of stem cells by using antibodies that target different CD34 epitopes yields different patterns of T-cell differentiation.
Otto M; Chen X; Martin WJ; Leung W; Knowles J; Holladay M; Houston J; Handgretinger R; Barfield RC
Stem Cells; 2007 Feb; 25(2):537-42. PubMed ID: 17023516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
